Zdrowie i gospodarka · 26/01/2016
FDA Clears IZBA (Travoprost Ophthalmic Solution) for Approval
The FDA has determined that IZBA, a 0.003 percent travoprost ophthalmic solution, was not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of abbreviated new drug applications.
Source: Federal Register — Food and Drug AdministrationOpen original release →